Condition
Histiocytic Sarcoma
ClinicalTrials.gov condition label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov condition label, found in 3 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
3 shownQ702 for the Treatment of Patients With Hematologic MalignanciesNCT06712810 · 2025-08-27
RECRUITINGCobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic DisordersNCT04079179 · 2021-04-19
RECRUITINGTargeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)NCT03155620 · 2017-07-31
ACTIVE_NOT_RECRUITINGCommon interventions
Biospecimen CollectionPROCEDURE2Computed TomographyPROCEDURE2Magnetic Resonance ImagingPROCEDURE2Positron Emission TomographyPROCEDURE2Axl/Mer/CSF1R Inhibitor Q702DRUG1Biopsy ProcedurePROCEDURE1Bone Marrow AspirationPROCEDURE1Bone Marrow Aspiration and BiopsyPROCEDURE1Bone Marrow BiopsyPROCEDURE1Bone ScanPROCEDURE1CobimetinibDRUG1EnsartinibDRUG1ErdafitinibDRUG1IvosidenibDRUG1Laboratory Biomarker AnalysisOTHER1Larotrectinib SulfateDRUG1Mutation Carrier ScreeningPROCEDURE1OlaparibDRUG1PalbociclibDRUG1Pharmacological StudyOTHER1Radionuclide ImagingPROCEDURE1SamotolisibDRUG1SelpercatinibDRUG1Selumetinib SulfateDRUG1Survey AdministrationOTHER1
Leading sponsors
Trial status mix
RECRUITING2
ACTIVE_NOT_RECRUITING1
Phase mix
PHASE22
PHASE11
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.